Share Price and Basic Stock Data
Last Updated: February 10, 2026, 10:29 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gian Lifecare Ltd operates within the Hospitals & Medical Services industry, with a current market capitalization of ₹10.8 Cr. The company’s recent revenue performance shows fluctuations, with quarterly sales recorded at ₹2.82 Cr in September 2022, peaking at ₹5.09 Cr in December 2022, before declining to ₹1.55 Cr in March 2023. The subsequent quarters showed a gradual recovery, with sales reaching ₹2.30 Cr in September 2023 and projected to rise to ₹3.79 Cr by December 2023. Over the trailing twelve months, total sales stood at ₹5.52 Cr, reflecting ongoing volatility in revenue generation. The operating profit margin (OPM) has also varied significantly, highlighting challenges in cost management, with OPM recorded at a low of -59.09% as of September 2025. This trend indicates a need for strategic adjustments to stabilize revenue streams and enhance operational efficiency.
Profitability and Efficiency Metrics
Gian Lifecare’s profitability metrics reveal a mixed performance trajectory. The company reported a net profit of ₹0.09 Cr, translating to a negative earnings per share (EPS) of -₹0.04 for the fiscal year 2025. The operating profit for the same period was ₹0.95 Cr, with an operating profit margin of 15.99%. However, the company recorded a significant decrease in profitability in recent quarters, with a net profit of ₹0.20 Cr in September 2023 and a decline to -₹0.46 Cr by September 2025. Efficiency metrics also indicate challenges, with a cash conversion cycle (CCC) of -555.94 days as of March 2025, reflecting poor management of working capital. The return on equity (ROE) stood at 0.81%, while the return on capital employed (ROCE) was a mere 3.00%, both lower than typical sector averages, suggesting inefficiencies in capital utilization.
Balance Sheet Strength and Financial Ratios
The balance sheet of Gian Lifecare Ltd presents a mixed picture of financial health. As of September 2025, total assets were valued at ₹33.77 Cr, with total liabilities amounting to ₹35.56 Cr, indicating a leverage scenario that may pose risks to financial stability. The company’s borrowings stood at ₹4.90 Cr, while reserves were reported at ₹9.01 Cr, reflecting a modest cushion against liabilities. The interest coverage ratio (ICR) of 2.30x suggests that Gian Lifecare can meet its interest obligations, although this ratio is significantly lower than industry norms. Financial ratios such as the price-to-book value (P/BV) at 0.92x and total debt-to-equity ratio at 0.30x indicate that the stock is trading below its book value, which may be attractive to value investors. However, the negative cash flow and declining profitability raise concerns regarding future financial sustainability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gian Lifecare Ltd has seen notable shifts, with promoter holdings declining from 60.68% in December 2022 to 32.09% by March 2025. This reduction in promoter stake may indicate a lack of confidence or strategic realignment. Public shareholding increased to 67.91% by December 2024, highlighting a growing interest from retail investors, with the number of shareholders rising to 4,285 as of September 2025. The absence of foreign institutional investment (FIIs) and domestic institutional investment (DIIs) reflects a cautious stance from institutional players, potentially due to the company’s erratic financial performance. Despite these shifts, the high public stake could provide stability, but the declining promoter interest could raise concerns regarding long-term strategic direction.
Outlook, Risks, and Final Insight
Gian Lifecare Ltd faces a challenging outlook characterized by both opportunities and risks. The company’s recent efforts to stabilize revenues and improve profitability may yield positive outcomes if managed effectively. However, the risks associated with declining margins, high leverage, and a negative cash conversion cycle could hinder growth prospects. The company’s ability to enhance operational efficiencies, manage costs, and restore profitability is crucial for regaining investor confidence. Additionally, external factors such as regulatory changes and competitive pressures within the healthcare sector could impact performance. In the absence of significant improvements in profitability and operational efficiency, Gian Lifecare may struggle to attract institutional investors and sustain its market position. A strategic focus on enhancing service offerings and operational management could potentially turn the tide for the company.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 48.2 Cr. | 144 | 187/120 | 117 | 2.43 % | 23.6 % | 20.7 % | 10.0 | |
| Global Longlife Hospital and Research Ltd | 13.5 Cr. | 12.8 | 33.0/12.8 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.2 Cr. | 9.89 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 105 Cr. | 55.8 | 98.7/52.2 | 23.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 19.3 Cr. | 3.58 | 6.12/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 25,758.00 Cr | 691.23 | 95.15 | 92.86 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.82 | 5.09 | 1.55 | 2.43 | 2.30 | 3.79 | 4.60 | 1.98 | 1.95 | 1.59 | 1.11 | 0.87 | 0.66 |
| Expenses | 2.33 | 2.80 | 2.27 | 1.92 | 1.97 | 1.55 | 1.49 | 1.76 | 1.72 | 1.11 | 1.12 | 0.73 | 1.05 |
| Operating Profit | 0.49 | 2.29 | -0.72 | 0.51 | 0.33 | 2.24 | 3.11 | 0.22 | 0.23 | 0.48 | -0.01 | 0.14 | -0.39 |
| OPM % | 17.38% | 44.99% | -46.45% | 20.99% | 14.35% | 59.10% | 67.61% | 11.11% | 11.79% | 30.19% | -0.90% | 16.09% | -59.09% |
| Other Income | 0.34 | 0.17 | 0.18 | 0.14 | 0.15 | 0.16 | 0.18 | 0.17 | 0.16 | 0.16 | -0.24 | 0.15 | 0.09 |
| Interest | 0.10 | 0.12 | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 |
| Depreciation | 0.11 | 0.14 | 0.12 | 0.13 | 0.13 | 0.13 | 0.07 | 0.12 | 0.12 | 0.12 | 0.11 | 0.11 | 0.11 |
| Profit before tax | 0.62 | 2.20 | -0.77 | 0.40 | 0.24 | 2.16 | 3.11 | 0.16 | 0.17 | 0.42 | -0.46 | 0.09 | -0.50 |
| Tax % | 14.52% | 13.64% | 18.18% | 35.00% | 16.67% | 24.54% | 29.26% | 37.50% | 11.76% | 9.52% | 4.35% | 33.33% | -8.00% |
| Net Profit | 0.53 | 1.89 | -0.90 | 0.26 | 0.20 | 1.63 | 2.20 | 0.11 | 0.14 | 0.38 | -0.48 | 0.05 | -0.46 |
| EPS in Rs | 0.51 | 1.83 | -0.87 | 0.25 | 0.19 | 1.58 | 2.13 | 0.11 | 0.14 | 0.37 | -0.46 | 0.05 | -0.44 |
Last Updated: February 1, 2026, 7:46 pm
Below is a detailed analysis of the quarterly data for Gian Lifecare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 0.66 Cr.. The value appears to be declining and may need further review. It has decreased from 0.87 Cr. (Jun 2025) to 0.66 Cr., marking a decrease of 0.21 Cr..
- For Expenses, as of Sep 2025, the value is 1.05 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.73 Cr. (Jun 2025) to 1.05 Cr., marking an increase of 0.32 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.39 Cr.. The value appears to be declining and may need further review. It has decreased from 0.14 Cr. (Jun 2025) to -0.39 Cr., marking a decrease of 0.53 Cr..
- For OPM %, as of Sep 2025, the value is -59.09%. The value appears to be declining and may need further review. It has decreased from 16.09% (Jun 2025) to -59.09%, marking a decrease of 75.18%.
- For Other Income, as of Sep 2025, the value is 0.09 Cr.. The value appears to be declining and may need further review. It has decreased from 0.15 Cr. (Jun 2025) to 0.09 Cr., marking a decrease of 0.06 Cr..
- For Interest, as of Sep 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.09 Cr..
- For Depreciation, as of Sep 2025, the value is 0.11 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.11 Cr..
- For Profit before tax, as of Sep 2025, the value is -0.50 Cr.. The value appears to be declining and may need further review. It has decreased from 0.09 Cr. (Jun 2025) to -0.50 Cr., marking a decrease of 0.59 Cr..
- For Tax %, as of Sep 2025, the value is -8.00%. The value appears to be improving (decreasing) as expected. It has decreased from 33.33% (Jun 2025) to -8.00%, marking a decrease of 41.33%.
- For Net Profit, as of Sep 2025, the value is -0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 0.05 Cr. (Jun 2025) to -0.46 Cr., marking a decrease of 0.51 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.44. The value appears to be declining and may need further review. It has decreased from 0.05 (Jun 2025) to -0.44, marking a decrease of 0.49.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:39 am
| Metric | Mar 2019n n 5m | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.56 | 7.31 | 10.24 | 15.45 | 11.41 | 12.78 | 5.94 | 5.52 |
| Expenses | 0.36 | 5.23 | 7.14 | 9.39 | 9.37 | 6.58 | 4.99 | 4.68 |
| Operating Profit | 0.20 | 2.08 | 3.10 | 6.06 | 2.04 | 6.20 | 0.95 | 0.84 |
| OPM % | 35.71% | 28.45% | 30.27% | 39.22% | 17.88% | 48.51% | 15.99% | 15.22% |
| Other Income | 0.00 | 0.10 | 0.29 | 0.51 | 0.69 | 0.64 | 0.25 | 0.23 |
| Interest | 0.04 | 0.37 | 0.35 | 0.39 | 0.45 | 0.47 | 0.43 | 0.39 |
| Depreciation | 0.02 | 0.26 | 0.29 | 0.33 | 0.50 | 0.46 | 0.47 | 0.46 |
| Profit before tax | 0.14 | 1.55 | 2.75 | 5.85 | 1.78 | 5.91 | 0.30 | 0.22 |
| Tax % | 21.43% | 28.39% | 26.91% | 25.30% | 29.78% | 27.24% | 46.67% | |
| Net Profit | 0.10 | 1.13 | 2.02 | 4.37 | 1.26 | 4.30 | 0.16 | 0.09 |
| EPS in Rs | 1.10 | 1.96 | 4.23 | 1.22 | 4.16 | 0.15 | 0.10 | |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 78.76% | 116.34% | -71.17% | 241.27% | -96.28% |
| Change in YoY Net Profit Growth (%) | 0.00% | 37.58% | -187.50% | 312.44% | -337.55% |
Gian Lifecare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -2% |
| 3 Years: | -25% |
| TTM: | -56% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -32% |
| 3 Years: | -67% |
| TTM: | -98% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | -22% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 11% |
| Last Year: | 1% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: February 1, 2026, 2:52 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 4.70 | 4.70 | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 |
| Reserves | 0.10 | 2.94 | 4.96 | 3.69 | 4.97 | 9.27 | 9.42 | 9.01 |
| Borrowings | 1.36 | 1.09 | 1.00 | 2.03 | 4.57 | 4.17 | 5.07 | 4.90 |
| Other Liabilities | 6.34 | 3.64 | 4.82 | 7.00 | 8.52 | 8.28 | 10.73 | 9.52 |
| Total Liabilities | 7.81 | 12.37 | 15.48 | 23.06 | 28.40 | 32.06 | 35.56 | 33.77 |
| Fixed Assets | 2.91 | 2.84 | 2.99 | 3.50 | 4.62 | 4.47 | 4.01 | 3.78 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.12 | 0.14 | 0.14 | 0.14 | 0.14 |
| Investments | 0.00 | 0.00 | 0.00 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
| Other Assets | 4.90 | 9.53 | 12.49 | 19.33 | 23.53 | 27.34 | 31.30 | 29.74 |
| Total Assets | 7.81 | 12.37 | 15.48 | 23.06 | 28.40 | 32.06 | 35.56 | 33.77 |
Below is a detailed analysis of the balance sheet data for Gian Lifecare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.34 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.34 Cr..
- For Reserves, as of Sep 2025, the value is 9.01 Cr.. The value appears to be declining and may need further review. It has decreased from 9.42 Cr. (Mar 2025) to 9.01 Cr., marking a decrease of 0.41 Cr..
- For Borrowings, as of Sep 2025, the value is 4.90 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 5.07 Cr. (Mar 2025) to 4.90 Cr., marking a decrease of 0.17 Cr..
- For Other Liabilities, as of Sep 2025, the value is 9.52 Cr.. The value appears to be improving (decreasing). It has decreased from 10.73 Cr. (Mar 2025) to 9.52 Cr., marking a decrease of 1.21 Cr..
- For Total Liabilities, as of Sep 2025, the value is 33.77 Cr.. The value appears to be improving (decreasing). It has decreased from 35.56 Cr. (Mar 2025) to 33.77 Cr., marking a decrease of 1.79 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.78 Cr.. The value appears to be declining and may need further review. It has decreased from 4.01 Cr. (Mar 2025) to 3.78 Cr., marking a decrease of 0.23 Cr..
- For CWIP, as of Sep 2025, the value is 0.14 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.14 Cr..
- For Investments, as of Sep 2025, the value is 0.11 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.11 Cr..
- For Other Assets, as of Sep 2025, the value is 29.74 Cr.. The value appears to be declining and may need further review. It has decreased from 31.30 Cr. (Mar 2025) to 29.74 Cr., marking a decrease of 1.56 Cr..
- For Total Assets, as of Sep 2025, the value is 33.77 Cr.. The value appears to be declining and may need further review. It has decreased from 35.56 Cr. (Mar 2025) to 33.77 Cr., marking a decrease of 1.79 Cr..
Notably, the Reserves (9.01 Cr.) exceed the Borrowings (4.90 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019n n 5m | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.20 | 0.99 | 2.10 | 4.03 | -2.53 | 2.03 | -4.12 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 860.36 | 78.39 | 73.07 | 42.05 | 103.97 | 137.37 | 335.27 |
| Inventory Days | 4,380.00 | 188.58 | |||||
| Days Payable | 5,266.43 | 1,079.79 | |||||
| Cash Conversion Cycle | -26.07 | 78.39 | 73.07 | 42.05 | 103.97 | 137.37 | -555.94 |
| Working Capital Days | -2,887.41 | -42.44 | -53.82 | -31.42 | -160.27 | -68.83 | -41.84 |
| ROCE % | 37.65% | 31.98% | 46.71% | 12.41% | 29.23% | 2.92% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -0.04 | 4.02 | 1.03 |
| Diluted EPS (Rs.) | -0.04 | 4.02 | 1.03 |
| Cash EPS (Rs.) | 0.57 | 4.53 | 1.51 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 18.59 | 18.64 | 14.62 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 18.59 | 18.64 | 14.62 |
| Revenue From Operations / Share (Rs.) | 6.41 | 12.69 | 11.53 |
| PBDIT / Share (Rs.) | 1.14 | 6.52 | 2.43 |
| PBIT / Share (Rs.) | 0.53 | 6.00 | 1.95 |
| PBT / Share (Rs.) | 0.03 | 5.56 | 1.54 |
| Net Profit / Share (Rs.) | -0.03 | 4.01 | 1.03 |
| NP After MI And SOA / Share (Rs.) | -0.03 | 4.01 | 1.03 |
| PBDIT Margin (%) | 17.78 | 51.38 | 21.09 |
| PBIT Margin (%) | 8.30 | 47.34 | 16.92 |
| PBT Margin (%) | 0.57 | 43.80 | 13.35 |
| Net Profit Margin (%) | -0.56 | 31.64 | 8.91 |
| NP After MI And SOA Margin (%) | -0.56 | 31.64 | 8.91 |
| Return on Networth / Equity (%) | -0.19 | 21.54 | 7.03 |
| Return on Capital Employeed (%) | 2.35 | 27.51 | 11.55 |
| Return On Assets (%) | -0.10 | 12.72 | 3.76 |
| Long Term Debt / Equity (X) | 0.16 | 0.11 | 0.10 |
| Total Debt / Equity (X) | 0.30 | 0.25 | 0.30 |
| Asset Turnover Ratio (%) | 0.19 | 0.43 | 0.00 |
| Current Ratio (X) | 1.45 | 1.31 | 1.07 |
| Quick Ratio (X) | 1.40 | 1.22 | 0.98 |
| Inventory Turnover Ratio (X) | 8.82 | 2.00 | 0.00 |
| Interest Coverage Ratio (X) | 2.30 | 14.54 | 5.92 |
| Interest Coverage Ratio (Post Tax) (X) | 0.92 | 9.96 | 3.50 |
| Enterprise Value (Cr.) | 16.65 | 24.19 | 16.40 |
| EV / Net Operating Revenue (X) | 2.51 | 1.84 | 1.38 |
| EV / EBITDA (X) | 14.12 | 3.59 | 6.52 |
| MarketCap / Net Operating Revenue (X) | 2.68 | 1.93 | 1.48 |
| Price / BV (X) | 0.92 | 1.31 | 1.16 |
| Price / Net Operating Revenue (X) | 2.68 | 1.93 | 1.48 |
| EarningsYield | 0.00 | 0.16 | 0.06 |
After reviewing the key financial ratios for Gian Lifecare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. It has decreased from 4.02 (Mar 24) to -0.04, marking a decrease of 4.06.
- For Diluted EPS (Rs.), as of Mar 25, the value is -0.04. This value is below the healthy minimum of 5. It has decreased from 4.02 (Mar 24) to -0.04, marking a decrease of 4.06.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 3. It has decreased from 4.53 (Mar 24) to 0.57, marking a decrease of 3.96.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.59. It has decreased from 18.64 (Mar 24) to 18.59, marking a decrease of 0.05.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.59. It has decreased from 18.64 (Mar 24) to 18.59, marking a decrease of 0.05.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 6.41. It has decreased from 12.69 (Mar 24) to 6.41, marking a decrease of 6.28.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.14. This value is below the healthy minimum of 2. It has decreased from 6.52 (Mar 24) to 1.14, marking a decrease of 5.38.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.53. This value is within the healthy range. It has decreased from 6.00 (Mar 24) to 0.53, marking a decrease of 5.47.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.03. This value is within the healthy range. It has decreased from 5.56 (Mar 24) to 0.03, marking a decrease of 5.53.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -0.03. This value is below the healthy minimum of 2. It has decreased from 4.01 (Mar 24) to -0.03, marking a decrease of 4.04.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -0.03. This value is below the healthy minimum of 2. It has decreased from 4.01 (Mar 24) to -0.03, marking a decrease of 4.04.
- For PBDIT Margin (%), as of Mar 25, the value is 17.78. This value is within the healthy range. It has decreased from 51.38 (Mar 24) to 17.78, marking a decrease of 33.60.
- For PBIT Margin (%), as of Mar 25, the value is 8.30. This value is below the healthy minimum of 10. It has decreased from 47.34 (Mar 24) to 8.30, marking a decrease of 39.04.
- For PBT Margin (%), as of Mar 25, the value is 0.57. This value is below the healthy minimum of 10. It has decreased from 43.80 (Mar 24) to 0.57, marking a decrease of 43.23.
- For Net Profit Margin (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 5. It has decreased from 31.64 (Mar 24) to -0.56, marking a decrease of 32.20.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -0.56. This value is below the healthy minimum of 8. It has decreased from 31.64 (Mar 24) to -0.56, marking a decrease of 32.20.
- For Return on Networth / Equity (%), as of Mar 25, the value is -0.19. This value is below the healthy minimum of 15. It has decreased from 21.54 (Mar 24) to -0.19, marking a decrease of 21.73.
- For Return on Capital Employeed (%), as of Mar 25, the value is 2.35. This value is below the healthy minimum of 10. It has decreased from 27.51 (Mar 24) to 2.35, marking a decrease of 25.16.
- For Return On Assets (%), as of Mar 25, the value is -0.10. This value is below the healthy minimum of 5. It has decreased from 12.72 (Mar 24) to -0.10, marking a decrease of 12.82.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 0.2. It has increased from 0.11 (Mar 24) to 0.16, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.30. This value is within the healthy range. It has increased from 0.25 (Mar 24) to 0.30, marking an increase of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.19. It has decreased from 0.43 (Mar 24) to 0.19, marking a decrease of 0.24.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.31 (Mar 24) to 1.45, marking an increase of 0.14.
- For Quick Ratio (X), as of Mar 25, the value is 1.40. This value is within the healthy range. It has increased from 1.22 (Mar 24) to 1.40, marking an increase of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.82. This value exceeds the healthy maximum of 8. It has increased from 2.00 (Mar 24) to 8.82, marking an increase of 6.82.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.30. This value is below the healthy minimum of 3. It has decreased from 14.54 (Mar 24) to 2.30, marking a decrease of 12.24.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 3. It has decreased from 9.96 (Mar 24) to 0.92, marking a decrease of 9.04.
- For Enterprise Value (Cr.), as of Mar 25, the value is 16.65. It has decreased from 24.19 (Mar 24) to 16.65, marking a decrease of 7.54.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.51. This value is within the healthy range. It has increased from 1.84 (Mar 24) to 2.51, marking an increase of 0.67.
- For EV / EBITDA (X), as of Mar 25, the value is 14.12. This value is within the healthy range. It has increased from 3.59 (Mar 24) to 14.12, marking an increase of 10.53.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 2.68, marking an increase of 0.75.
- For Price / BV (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.31 (Mar 24) to 0.92, marking a decrease of 0.39.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.68. This value is within the healthy range. It has increased from 1.93 (Mar 24) to 2.68, marking an increase of 0.75.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gian Lifecare Ltd:
- Net Profit Margin: -0.56%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 2.35% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.19% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0.92
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.4
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 95.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.3
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.56%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 7/216(6), Swaroop Nagar, Kanpur Uttar Pradesh 208002 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Arun Kumar Gupta | Managing Director |
| Mrs. Rashika Agarwal | Non Executive Woman Director |
| Mr. Abhiram Saran Agarwal | Ind. Non-Executive Director |
| Mr. Umang Gupta | Ind. Non-Executive Director |
| Mr. Ramesh Yadav | Ind. Non-Executive Director |
| Mr. Shivam Mamgain | Non Executive Director |
FAQ
What is the intrinsic value of Gian Lifecare Ltd?
Gian Lifecare Ltd's intrinsic value (as of 11 February 2026) is ₹0.87 which is 91.20% lower the current market price of ₹9.89, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹10.2 Cr. market cap, FY2025-2026 high/low of ₹20.5/7.08, reserves of ₹9.01 Cr, and liabilities of ₹33.77 Cr.
What is the Market Cap of Gian Lifecare Ltd?
The Market Cap of Gian Lifecare Ltd is 10.2 Cr..
What is the current Stock Price of Gian Lifecare Ltd as on 11 February 2026?
The current stock price of Gian Lifecare Ltd as on 11 February 2026 is ₹9.89.
What is the High / Low of Gian Lifecare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gian Lifecare Ltd stocks is ₹20.5/7.08.
What is the Stock P/E of Gian Lifecare Ltd?
The Stock P/E of Gian Lifecare Ltd is .
What is the Book Value of Gian Lifecare Ltd?
The Book Value of Gian Lifecare Ltd is 18.7.
What is the Dividend Yield of Gian Lifecare Ltd?
The Dividend Yield of Gian Lifecare Ltd is 0.00 %.
What is the ROCE of Gian Lifecare Ltd?
The ROCE of Gian Lifecare Ltd is 3.00 %.
What is the ROE of Gian Lifecare Ltd?
The ROE of Gian Lifecare Ltd is 0.81 %.
What is the Face Value of Gian Lifecare Ltd?
The Face Value of Gian Lifecare Ltd is 10.0.